Multiple myeloma, which ranks as the second most common hematological malignancy, is
known for its great genetic heterogeneity. One pathway, however, stands out in this diverse …

Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell proliferative
disorder with a very poor prognosis and with distinct biologic, clinical, and laboratory …

Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that
originates either as primary disease (pPCL) or as a secondary leukemic transformation …

Various translocations and mutations have been identified in myeloma, and certain
aberrations, such as t (4; 14) and del17, are linked with disease prognosis. To investigate …

Plasma cell leukemia (PCL) is a rare, yet aggressive plasma cell (PC) neoplasm, variant of
multiple myeloma (MM), characterized by high levels of PCs circulating in the peripheral …

B-cell lymphomas comprise an increasing number of clinicopathological entities whose
characterization has historically been based mainly on histopathological features. In recent …

Plasma cell leukemia (PCL) is an aggressive variant of multiple myeloma and is
characterized by the presence of> 20% and/or an absolute number of greater 2× 10 (9)/L …

As gamopatias monoclonais constituem um grupo de desordens caracterizado pela
proliferação monoclonal de plasmócitos, que produzem e secretam imunoglobulina ou …

Multiple myeloma has an incidence rate of 102,000 and death rate of 72,000 people per
year worldwide. The incidence varies by ethnicity with highest rates observed in African …

Multiple myeloma is an incurable malignant expansion of plasma cells in the bone marrow.
Although there is no pathognomonic genetic lesion among multiple myeloma patients …